Product Information
Registration Status: ActiveREBIF SOLUTION FOR INJECTION IN CARTRIDGE 22MCG/0.5ML is approved to be sold in Singapore with effective from 2011-06-17. It is marketed by MERCK PTE LTD, with the registration number of SIN13974P.
This product contains Interferon Beta-1A 22mcg/0.5ml in the form of INJECTION, SOLUTION. It is approved for SUBCUTANEOUS use.
This product is manufactured by Merck Serono S.p.A (Bari) in ITALY.
It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.
Description
Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta.
Indication
For treatment of relapsing/remitting multiple sclerosis, also for condyloma acuminatum
Mechanism of Action
Interferon beta binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription) which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon beta binds more stably to type I interferon receptors than interferon alpha.
Clearance
* 33-55 L/hour [Healthy SC injection of 60 mcg]
Active Ingredient/Synonyms
Interferon beta 1-a | Interferon beta 1a | Interferon beta-1a (recombinant human) | Interferon beta-1a,recombinant | Interferon-beta-1a | Interferon beta-1a |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.